Combination of Durvalumab and Tremelimumab May Prolong OS in CRC

This phase II trial suggested that combination immune checkpoint inhibition with durvalumab plus tremelimumab may be associated with prolonged overall survival in patients with advanced refractory colorectal cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news